The scale of the current outbreak of Ebola virus disease in west Africa is staggering. Thousands of infections and deaths have been reported in recent months, and unless major changes occur in the situation, incidence of Ebola virus disease has been projected to continue to grow and cumulative incidence to exceed 20 000 by November.
1 A humanitarian crisis that stretches far beyond the impact of Ebola virus infections is unfolding in Africa, devastating the health systems and economies in aff ected countries. 2 In the present outbreak, most infections remain confi ned to west Africa, although four cases have been detected outside this region: three cases diagnosed in Dallas, USA (of which one infection was contracted in Liberia and two were associated with nosocomial transmission from the fi rst case), and one case in Madrid, Spain, associated with nosocomial transmission (fi gure).
In The Lancet, Isaac Bogoch and colleagues 3 report on the potential for international dissemination of Ebola virus disease. Their assessment of risk for diff erent countries is an advance over previous work, 4 which analysed fl ight networks and connectivity, but did not account for passenger fl ows and fi nal destinations. Because of the assumptions of uniform risk across the population and constant prevalence of infection (whereas, in fact, risk within the population is not likely to be uniform and incidence is doubling every 15-30 days), 
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Among all reported cases in the 2014 outbreak to date, most infections have been contracted in three countries in west Africa: Guinea, Liberia, and Sierra Leone.
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Travelled to country without previous diagnosis Transfer after diagnosis Cases diagnosed in west Africa and transferred for medical treatment Case with infection in west Africa but diagnosed outside west Africa Cases with infection and diagnosis outside west Africa Madrid Dallas the relative risks comparing diff erent countries can be more valuable than the estimated absolute risks. Bogoch and colleagues report that the two countries at highest risk of receiving cases are Ghana and Senegal and, outside Africa, the risk for export to the UK or France combined was estimated to be about eight times higher than the risk for export to the USA (15·8 vs 2·0). 3 In other words, for every case of Ebola virus disease exported to the USA, the authors predict that there will be roughly eight cases exported to the UK or France combined.
Bogoch and colleagues 3 then studied the potential for exit and entry screening to reduce export of unidentifi ed infections, concluding that exit screening would be a much more effi cient approach than entry screening. We would like to add several points to this discussion. First, international support would be essential for implementation of exit screening in the three highly-aff ected resource-poor countries in west Africa. However, implementation of more stringent checks beyond what is already being done could be very challenging. The aff ected countries have many urgent priorities-resources including money, personnel, medical equipment, and supplies are urgently needed to expand capacity for detection, diagnosis, and treatment of patients with Ebola virus disease, and to implement isolation and contact tracing, which are currently the best available interventions to control the outbreak. Meanwhile, the outbreak is having a catastrophic eff ect on the local health-care systems, which were already fragile.
2, 5 No announcements have been made yet about earmarked contributions from the international community to support exit screening.
Second, exit and entry screening might not have a substantial eff ect on export rates, because of the long incubation period of the disease (average 8-10 days, range 2-21 days), 1 combined with rapid disease progression after onset, so that most exportations would be incubating infections missed at border screening points. Finally, a choice is posed between entry and exit screening in Bogoch and colleagues' study, 3 with exit screening shown to be more effi cient than entry screening and the combination of entry and exit screening shown to have little incremental usefulness. However, some countries have implemented and will continue entry screening 6, 7 for various reasons. Subject to entry screening already being implemented, exit screening from the aff ected countries might not have incremental utility, especially considering the other urgent priorities in the region. In addition to any entry or exit screening, vigilance within countries is essential for early detection of imported cases of Ebola virus disease. 3 There are several important near-future research needs. Perhaps most urgent is a better understanding of the eff ectiveness of existing treatment options, including convalescent serum. In the medium term, it is hoped that new vaccines and drugs will be available quickly for human clinical trials and in exposed populations. 8 The WHO Ebola Response team has neatly summarised the transmission dynamics and epidemiological characteristics including the reproductive number, incubation period, and case fatality risk in the current Ebola virus outbreak, 1 but one important unknown is the proportion of infections that are asymptomatic or mildly symptomatic. If mild infections do occur and are infectious, disease control outside west Africa might be increasingly challenging. However, this scenario is thought to be unlikely. 9 One particularly pressing need is for the reassessment of appropriate procedures for infection control, and the potential for the virus to spread via small particle aerosols 10 in addition to via contact with infected patients or their bodily fl uids. Infection of health-care personnel in west Africa is often attributed to the scarcity of appropriate protective equipment and supplies, or inadequate administrative controls. 11, 12 However, the nosocomial cases in Dallas and Madrid have raised the concern that present protocols might not be suffi cient to protect health-care personnel fully against infection, particularly if cases are managed in health-care facilities that are not fully prepared.
In The Lancet, Ben Slotman and colleagues report the results of a phase 3 trial of thoracic radiotherapy for small-cell lung cancer.
1 The trial is the most recent in a long line of studies showing that local radiotherapy benefi ts patients with small-cell lung cancer, a disease characterised by a bulky intrathoracic mass at presentation, a high propensity for metastasis, and high chemosensitivity, but with a poor prognosis.
2
Combination of diff erent modalities of cancer treatment off ers several advantages. Reduction of the bulk of the tumour will increase blood fl ow and oxygenation to the tumour. The absence of overlapping toxic eff ects enables full eff ective doses of each treatment modality to be maintained, important for surmounting resistance to any one modality. Pignon and colleagues 3 described a 5% benefi t in survival at 3 years when thoracic radiotherapy was added to induction chemotherapy for patients with limited stage disease. The benefi t did not become apparent until about a year after randomisation.
De Ruysscher and co-workers confi rmed a postulated interaction between chest irradiation and chemotherapy by showing better long-term survival if the overall treatment time for radiotherapy was shorter than 30 days. 4 This approach requires concomitant administration of both treatments and accelerated fractionation of radiotherapy. Furthermore, combined treatment modalities enable the eradication of micrometastatic disease in pharmacological sanctuarieseg, the brain. A reduction in the incidence of symptomatic brain metastases and a 6% benefi t in overall survival at 3 years were reported with the sequential addition of prophylactic cranial irradiation in responding patients with stage 1-3 disease. 5 The European Organisation for Research and Treatment of Cancer reported a doubling of 1-year survival with cranial irradiation in responding patients with extensive stage disease without a deleterious eff ect on overall health status. 6 It took several decades and the pooling of data from hundreds of patients to obtain these results, but combined chemotherapy and prophylactic cranial irradiation are now considered the standard of care in many clinical guidelines. 7 The next logical step was to irradiate the tumour bulk in patients with clinically evident metastases. Slotman and colleagues 1 randomly assigned nearly 500 patients responding to fi rst-line chemotherapy to either standard follow-up or thoracic irradiation consisting of ten fractions of 3 Gy. All patients underwent prophylactic cranial irradiation and no serious toxic eff ects were reported. Similar to early stage disease, the survival curves separated only at nine months after randomisation, favouring the thoracic radiotherapy group by 18 months. At 2 years, overall survival was 13% in the group of patients receiving thoracic radiotherapy versus 3% without radiotherapy; the number needed to treat for one more patient to survive for 2 years was 10·6. Presumably, the competing risk of death caused by extrathoracic metastatic disease that is refractory to chemotherapy becomes less important than the risk caused by uncontrolled disease at the primary site in unirradiated patients at 2 years. Hence, there is an ongoing need for development of novel drugs targeted against molecular alterations in small-cell lung cancer. 8 The rationale for Slotman and colleagues' study was sound: intrathoracic progression was common in a previous trial of prophylactic cranial irradiation for patients Small-cell lung cancer: local therapy for a systemic disease?
